NEW YORK (GenomeWeb) – Bio-Techne today announced a deal to buy protein analysis technology firm ProteinSimple for $300 million in cash.
ProteinSimple has appointed Joe Keegan and Chris van Ingen to its board of directors.
Keegan was previously the CEO of ForteBio and Molecular Devices.
Quanterix this week launched a commercial, research-use-only version of its Single Molecule Array, Simoa, platform.
ProteinSimple said this week that it has hired Terry Salyer as vice president of sales.
By Adam Bonislawski
A team led by Stanford University researchers has developed a method for predicting response to cancer therapies based on cellular signaling protein dynamics and changes in tumor size.
By a GenomeWeb staff reporter
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.